Szarek, M., Bittner, V. A., Aylward, P., Baccara-Dinet, M., Bhatt, D. L., Diaz, R., . . . Schwartz, G. G. (2020). Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J.
Chicago Style citaatSzarek, Michael, et al. "Lipoprotein(a) Lowering By Alirocumab Reduces the Total Burden of Cardiovascular Events Independent of Low-density Lipoprotein Cholesterol Lowering: ODYSSEY OUTCOMES Trial." Eur Heart J 2020.
MLA citatieSzarek, Michael, et al. "Lipoprotein(a) Lowering By Alirocumab Reduces the Total Burden of Cardiovascular Events Independent of Low-density Lipoprotein Cholesterol Lowering: ODYSSEY OUTCOMES Trial." Eur Heart J 2020.